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Abstract
Background: Immunosuppressive regimens in renal transplantation frequently contain corticosteroids, but many
centers withdraw steroids as a consequence of unwanted side effects of steroids. The optimal timing to withdraw
steroids after transplantation, however, remains unclear. The aim of this study was to determine an optimal time
point following kidney transplantation that is associated with reduced mortality without jeopardizing the allograft
to allow safe discontinuation of steroids.
Methods: We conducted a retrospective cohort study and computed a concatenated landmark-stratified Cox
supermodel to estimate hazard ratios and 95% confidence intervals for mortality and graft loss using dynamic
propensity score matching to adjust for confounding by indication.
Results: A total of 6070 first kidney transplant recipients in the Austrian Dialysis and Transplant Registry who
were transplanted between 1990 and 2012 were evaluated and classified according to steroid treatment status
throughout follow-up after kidney transplantation; 2142 patients were withdrawn from steroids during the study
period. Overall, 1131 patients lost their graft and 821 patients in the study cohort died. Steroid withdrawal within
18 months after transplantation was associated with an increased rate of graft loss compared to steroid maintenance
during that time (6 months after transplantation: HR = 1.8; 95% CI, 1.3 to 2.6; 18 months after transplantation: HR = 1.3;
95% CI, 1.1 to 1.6; 24 months after transplantation: HR = 1.2; 95% CI, 0.9 to 1.5), while mortality was not different
between groups.
Conclusions: Our findings suggest that steroid withdrawal after anti-IL-2 induction in the first 18 months after
transplantation is associated with an increased risk of allograft loss.
Keywords: Corticosteroids, Steroid withdrawal, Steroid maintenance, Immunosuppression, Kidney transplantation,
Graft loss
Background
Kidney transplantation is the most cost-effective treat-
ment option for eligible patients with end-stage renal
disease since transplantation is superior in terms of
quality and quantity of life whilst being less costly com-
pared to long-term dialysis treatment [1–6]. However,
choosing the appropriate immunosuppressive treatment
strategy is a key decision for sustained allograft function.
Despite the development of novel immunosuppressants
in recent years, serious side effects, such as increased
cardiovascular risk, impaired immune system detection
of cancer cells and antiviral defense, still result from
long-term intake of immunosuppressive drugs. There-
fore, various strategies to reduce immunosuppression
are being investigated with the aim to alleviate toxicity
associated with this treatment [7–11].
Maintenance immunosuppression usually consists of
three components, one of which is frequently a cortico-
steroid. Steroids are effective in preventing acute
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rejection, which is one of the main risk factors for re-
duced long-term graft survival when not appropriately
diagnosed and treated [12, 13]. Although triple im-
munosuppression allows lower steroid doses, the disad-
vantageous association of steroids with weight gain,
hyperlipidemia, high blood pressure, impaired glucose
metabolism, and osteoporosis persists [14–21]. Conse-
quently, several randomized trials have been performed
to investigate the efficacy of steroid withdrawal after
kidney transplantation. However, clinical trials can only
investigate withdrawal at a specific time point, which
likely may not be the optimal choice. While earlier
meta-analyses of these trials reported an increased rate
of acute rejections and graft loss after steroid with-
drawal compared with steroid maintenance, more re-
cent meta-analyses included trials conducted with
newer immunosuppressants and found no difference in
graft loss [10, 22–24]. Although the increased risk of
acute rejection persisted, subgroup analyses indicated
that contemporary immunosuppression reduced the
risk of acute rejection, and steroid withdrawal 3–6
months following kidney transplantation was suggested.
In contradiction, current clinical practice guidelines
discourage steroid withdrawal beyond the first week
after engraftment [25]. In view of this inconsistency of
recommendations, steroid withdrawal is managed dif-
ferently in clinical practice and there is no consensus
on the optimal timing for steroid withdrawal after kid-
ney transplantation. Likewise, long-term outcomes after
steroid withdrawal remain uncertain to date due to the
limited follow-up in rather small randomized trials [11].
The aim of the present study was to evaluate long-
term outcomes on graft and patient survival following
steroid withdrawal compared to steroid maintenance at
various points in time after kidney transplantation in
order to determine optimal timing for steroid with-
drawal in kidney transplant recipients. Our hypothesis
was that discontinuation of steroid treatment after a
‘certain’ treatment duration could improve patient sur-
vival through a reduction in toxicity associated with pro-
longed steroid maintenance without jeopardizing allograft
survival.
Methods
Study design and data sources
We conducted a retrospective open cohort study to in-
vestigate the effect of steroid withdrawal at numerous
points in time following kidney transplantation on pa-
tient and graft survival using data from three sources:
the OEstereichische (Austrian) Dialysis and Transplant
Registry (OEDTR), the EUROTRANSPLANT database,
and the Vienna Kidney Biopsy Registry, as previously
done by our group [26, 27]. The OEDTR was established
by the Austrian Society of Nephrology in 1970 and has
almost complete follow-up – only 0.6% of all Austrian
residents on renal replacement therapy have been lost
since 1990. The OEDTR contains thoroughly extracted
data from the original medical records in which the ori-
ginal data was assessed at the time of the follow-up visit
by the responsible physician [28]. Data provided by the
OEDTR included recipient age and sex, date of trans-
plantation, primary renal diagnosis, the presence of co-
morbidities at transplantation and annually throughout
follow-up, panel reactive antibodies, patient and graft
survival, and immunosuppression. Use of immunosup-
pressive medication was reported quarterly in the first
year after transplantation and annually thereafter. Induc-
tion treatment consisted of IL-2 antibodies. We retrieved
data on donor age and type (deceased or living), the
number of human leukocyte antigen mismatches, and
cold ischemia time from the EUROTRANSPLANT data-
base, which was established in 1968 and holds complete
entries of organ donor characteristics from transplants
that have been performed in the EUROTRANSPLANT
region to which Austria belongs [29]. Information on bi-
opsy confirmed acute rejection defined according to
Banff 97 criteria were extracted from the Vienna Kidney
Biopsy Registry, which is composed of standardized de-
scriptions of renal histopathology of native and trans-
plant kidney biopsies [30].
All end-stage renal disease patients recorded in the
OEDTR who received their first single-organ, ABO-
compatible kidney transplant between January 1, 1990,
and December 31, 2012, with an initial steroid-containing
immunosuppressive regimen were included in this
study and followed up until November 19, 2014.
The exposure of interest, ‘steroid withdrawal’, is a di-
chotomous time-dependent variable. Outcome variables
were functional graft loss and all-cause death with func-
tional graft. We performed cause-specific analyses of
either event type. Graft survival time was defined as the
time from transplantation until either permanent return
to dialysis treatment or second transplantation, counting
death or end of follow-up as censored observations.
Patient survival time was defined as the time from first
kidney transplantation until death, censored for graft
loss, and end of follow-up.
Statistical analyses
Continuous variables are expressed by mean and
standard deviation, categorical variables are presented
by frequencies and percentages.
To investigate the long-term effects of steroid with-
drawal at various time points after kidney transplant-
ation, we chose the landmarking approach, by which
causal effects can be inferred under the usual assump-
tions of propensity score analyses [31]. Specific points in
time following engraftment, so called landmark times,
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were pre-defined at 3-month intervals until 10 years after
engraftment. At each of these landmark times, study par-
ticipants were classified as either ‘steroid withdrawal’ or
‘steroid maintenance’ depending on steroid treatment sta-
tus within the preceding time interval (first day after pre-
vious landmark time until current landmark time). Once
patients were classified as ‘steroid withdrawal’ at a specific
landmark time they were excluded from consideration at
subsequent landmark times (Additional file 1: Figure S1).
Confounding by indication, caused by any potential
difference in covariates between patients withdrawn
from steroids and patients maintained on steroids that
could have influenced the decision to withdraw or
maintain steroids at a given landmark time, was ad-
dressed by introducing a landmark-time-dependent
propensity score for matching steroid-maintenance pa-
tients to steroid-withdrawal patients at each landmark
time [32–34]. First, we computed a logistic regression
model to calculate the probability of steroid withdrawal
or maintenance for each patient in the risk set at each
landmark time based on the most recent values of con-
founding covariates (Additional file 1: Figure S2). As a
second step, we matched patients withdrawn from ste-
roids to patients maintained on steroids based on these
individual propensity scores at each landmark time to
generate a cohort of steroid withdrawal and steroid
maintenance patients whose only remaining difference,
in theory, is the steroid treatment status at a given
landmark time. Using these matched study cohorts, we
computed cause-specific cumulative incidence func-
tions for the competing event type graft loss and death
with functional graft and compared them between
steroid treatment groups at specific landmark times. To
summarize differences in graft loss and mortality fol-
lowing steroid withdrawal or maintenance at different
time points, we estimated a landmark-stratified Cox
supermodel using all matched study cohort data from
all landmarks. In this supermodel, we included an inter-
action of steroid withdrawal status with landmark time,
smoothing transitions between neighboring points in time
using restricted cubic splines with knots at 1, 2, and 4 years
[35–37]. This approach yielded the landmark-specific,
propensity score-adjusted hazard ratios and 95% confi-
dence intervals from which the time point with the largest
benefit from discontinuation of steroids could be deter-
mined. Assessment of the proportional hazards assump-
tion was conducted using a log minus log plot based on
the cause-specific cumulative hazard estimated by the
Kaplan–Meier method with weights according to the
matching procedure. To deal with missing data in the co-
variates used for the propensity score, multiple imputation
was employed [38, 39]. For steroid withdrawal status (the
exposure of interest), no imputations were necessary. To
determine whether biomarkers of cardiovascular risk
improved after steroid withdrawal, we compared serum
cholesterol, fasting glucose, the number of antihyperten-
sive drugs, and body mass index before and after steroid
withdrawal (Additional file 1).
A 95% confidence interval excluding parity or a two-
sided P value less than 0.05 was considered as indication
for statistical significance. For all analyses, the software
R (version 3.2.1) was used. The study was approved by
the Ethics Committee of the Medical University Vienna
(1359/2014) and performed in accordance with the
Declaration of Helsinki. The detailed statistical methods
are outlined in Additional file 1.
Results
Patient characteristics at transplantation
We identified 6070 first kidney transplant recipients
within the observation period in the Austrian Dialysis
and Transplant Registry who met our inclusion criteria.
We excluded 900 patients, because the initial immuno-
suppressive regimen did not contain steroids or entries
were missing.
The baseline characteristics of the study cohort at
transplantation and stratified by steroid treatment status
3 years after transplantation are listed in Table 1. At
transplantation, the study cohort was 48 (±15) years old
on average and most were men (64%); 94% of the pa-
tients received an immunosuppressive regimen based on
a calcineurin inhibitor. The prevalence of diabetes was
27%, and 83% of the patients had arterial hypertension.
Three years after transplantation, more patients in the
steroid withdrawal group had diabetes mellitus com-
pared to patients who were maintained on steroids at
that time, suggesting a clinical indication (39% vs. 17%),
Table 1 Baseline characteristics of study participants at
transplantation
Characteristics n At transplantation
Number of patients 5170
Recipient age, years (mean ± SD) 5170 48 (15)
Female recipients, n (%) 5170 1876 (36)
Diabetes mellitus, n (%) 3088 839 (27)
Arterial hypertension, n (%) 3217 2686 (83)
Living donor, n (%) 5116 645 (13)
Donor age, years (mean ± SD) 5108 46 (16)
Sum of human leukocyte antigen
mismatch (mean ± SD)
4493 2.9 (1.3)
Immunosuppression, n (%) 5170
Cyclosporine A-based regimen 2579 (50)
Tacrolimus-based regimen 2287 (44)
Other regimen 304 (6)
Continuous variables are described with mean and standard deviation and
categorical variables with frequency and percentage
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but characteristics were otherwise similar between the
two groups as well as compared with baseline at trans-
plantation. After adjustment for this confounding by in-
dication using propensity score-matched cohorts, the
difference in diabetes between the two treatment groups
was greatly reduced to 16% versus 13% (Table 2).
In total, 2142 patients were withdrawn from steroids
within the study period (Fig. 1, Additional file 1:
Figure S3). Median follow-up time was 6.5 years (25th
percentile: 2.5 years; 75th percentile: 9.5 years). The
fitted propensity score models to estimate the prob-
ability for steroid withdrawal at each landmark are
shown in Additional file 1: Table S1, and reached a
median concordance index of 0.68 (25th percentile:
0.61; 75th percentile: 0.71).
Functional graft loss
Overall, 1131 patients in our study cohort lost their graft
within the study period. In the landmark Cox super-
model the rate of graft loss was significantly higher for
patients who were withdrawn from steroids within the
first 18 months after transplantation compared to ster-
oid maintenance during this time (6 months after trans-
plantation: HR = 1.8; 95% CI, 1.3 to 2.6; 12 months after
transplantation: HR = 1.6; 95% CI, 1.2 to 2.0; 18 months
after transplantation: HR = 1.3; 95% CI, 1.1 to 1.6;
24 months after transplantation: HR = 1.2; 95% CI, 0.9
to 1.5; Fig. 2). This is supported by significantly more
acute rejections in the withdrawal group if steroids
were discontinued within the first 12 months after
transplantation (17.6% vs. 7.2% within the first 6 months
after transplantation, P < 0.001; 1.6% vs. 0.4% between 7
and 12 months after transplantation, P < 0.001; Table 3).
Steroid withdrawal beyond 2 years after transplantation
did not have an effect on graft loss (three years after
transplantation: HR = 1.0, 95% CI, 0.8 to 1.3; 6 years
after transplantation: HR = 0.9; 95% CI, 0.7 to 1.3).
All-cause mortality with functional graft
A total of 821 patients with a functional graft died
within the study period, 303 due to cardiovascular
causes, 208 as a result of infections, 122 due to malig-
nancies, and 188 from other causes. We found no sig-
nificant difference in all-cause mortality with functional
graft between patients who were withdrawn from ste-
roids and patients who were still receiving steroids at
any landmark time in the landmark Cox supermodel
(6 months after transplantation: HR = 1.4; 95% CI, 0.9 to
2.0; 1 year after transplantation: HR = 1.3; 95% CI, 1.0 to
1.8; 3 years after transplantation: HR = 1.2; 95% CI, 0.8
to 1.7; 6 years after transplantation: HR = 0.8; 95% CI,
0.5 to 1.3; Fig. 3).
For both outcomes, assessment of proportional hazards
suggested some possible time-dependence of hazard ra-
tios, yet with introduction of administrative censoring
after 5 years, the estimated average hazard ratios were
virtually unchanged compared to our main unrestricted
analysis. Similarly, sensitivity analyses of our imputation
approach indicated robust results (Additional file 1:
Figure S4–Figure S7).
Table 2 Crude and matched characteristics of study participants 3 years after transplantation; 294 grafts were lost and 210 deaths
occurred by 3 years after transplantation
3 years after transplantation
Crude Matched
Characteristics n Steroid
withdrawal
n Steroid
maintenance
SMD n Steroid
withdrawal
n Steroid
maintenance
SMD
Number of patients 1272 2781 884 1203
Recipient age, years (mean ± SD) 1272 49 (14) 2781 47 (16) 11% 884 48 (14) 1203 46 (16) 9%
Female recipients, n (%) 1272 495 (39) 2781 1012 (36) 5% 884 348 (39) 1203 457 (38) 3%
Diabetes mellitus, n (%) 750 290 (39) 1828 309 (17) 52% 465 74 (16) 750 100 (13) 7%
Arterial hypertension, n (%) 957 814 (85) 1922 1607 (84) 4% 655 543 (83) 810 675 (83) 2%
Living donor, n (%) 1266 180 (14) 2735 323 (12) 7% 880 117 (13) 1178 144 (12) 3%
Donor age, years (mean ± SD) 1261 43 (16) 2732 45 (16) 10% 877 44 (15) 1175 44 (16) 4%
Sum of human leukocyte antigen
mismatch (mean ± SD)
1117 3.1 (1.4) 2435 2.6 (1.3) 38% 604 2.9 (1.3) 839 2.8 (1.3) 5%
Immunosuppression, n (%) 1272 2781 884 1203
Cyclosporine A-based regimen 648 (51) 1673 (60) 19% 493 (56) 771 (64) 17%
Tacrolimus-based regimen 601 (47) 1004 (36) 23% 376 (43) 419 (35) 16%
Other regimen 23 (2) 104 (4) 11% 15 (2) 13 (1) 6%
Continuous variables are described with mean and standard deviation and categorical variables with frequency and percentage. Standardized mean difference
(SMD) between steroid withdrawal and steroid maintenance groups were calculated for each covariate to quantify the difference between treatment groups.
Time-dependent propensity score matching greatly reduced the difference in covariates between the two treatment groups
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The comparisons of cardiovascular risk factors before
and after steroid withdrawal showed that there was no
difference in any of these cardiovascular surrogate out-
comes (Additional file 1: Figure S8).
Discussion
Our study is the first to evaluate various time points of
steroid withdrawal following kidney transplantation using
time point-specific propensity score matching and dy-
namic prediction by land-marking. Our results demon-
strate that steroid withdrawal within the first 18 months
after transplantation is associated with an increased rate
of graft loss compared to steroid maintenance during that
time, while mortality is unaffected by steroid withdrawal
at any time point after transplantation compared to ster-
oid maintenance.
Since a Canadian trial from the early 90s reported an
increased rate of graft loss after steroid withdrawal com-
pared to cyclosporine and steroids, more recent trials with
contemporary immunosuppression consistently concluded
that graft loss and mortality was not different between
patients who were withdrawn from steroids compared to
patients who received steroids, even if steroids were elimi-
nated within the first days after engraftment [40–45]. It
has been argued that IL-2 antibody induction and the
combined use of tacrolimus and mycophenolate mofetil
potentially facilitated safe steroid withdrawal [46]. Of note,
the majority of these trials followed patients for up to
Fig. 1 Shows the number of patients at risk, who were alive with a functioning graft throughout follow-up after transplantation in total and
according to steroid treatment status
Fig. 2 Shows hazard ratios and 95% confidence intervals for functional graft loss estimated from the Cox supermodel. The rate of graft loss
was higher when steroids were withdrawn within the first 2 years after transplantation, while graft loss was unaffected by steroid withdrawal
at later landmarks
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12 months only, and in light of this limited follow-up dur-
ation of rather small sample sizes, pooled analyses were
likewise unable to show a difference in graft and patient
survival following steroid withdrawal compared to steroid
maintenance [11, 24]. Taking into account that approxi-
mately a third of the trials investigating steroid withdrawal
inexplicably did not report these important outcomes, bias
from selective outcome reporting must also be considered.
Although clinical trials are the gold standard to investigate
treatment effects, the currently available information from
controlled data on long-term outcomes after steroid with-
drawal is scarce. Besides this uncertainty, neither random-
ized trials, which can only investigate the effects of steroid
withdrawal at one point in time, nor meta-analyses, which
pool data of various time points into one analysis, are
designed to determine an optimal timing for steroid with-
drawal after kidney transplantation. Similarly, a large
retrospective registry analysis from 2005 investigated
steroid withdrawal in kidney transplant recipients but did
not address the effect of different time points to withdraw
steroids following transplantation [47]. The majority of
trials investigated steroid withdrawal between 3 and
6 months after transplantation and outcomes following
steroid withdrawal at later time points are particularly
uncertain.
In agreement with others, we found that steroid with-
drawal was associated with an increased risk of acute re-
jection, but in contrast to previous reports, our results
revealed an increased rate of graft loss following steroid
withdrawal within the first 18 months after transplant-
ation compared to steroid maintenance during this time.
Although an increased risk of acute rejection does not
necessarily imply an increased rate of graft loss, we
argue that the majority of trials were too small, with
fewer than 300 participants, and too short, with a
follow-up between 1 and 3 years, to determine long-
term outcomes. It is not surprising that the rate of graft
loss, as shown in our analysis, is higher if steroids are
withdrawn within the first 18 months following engraft-
ment as the immunological risk is higher earlier after
transplantation. It is reasonable to assume that graft loss
requires a larger amount of time to develop compared to
acute rejection, which is an earlier outcome and is thus
not observed in clinical trials. Our findings challenge
current recommendations to abstain from steroid with-
drawal in kidney transplantation beyond 1 week after
engraftment, as well as proposals for safe steroid with-
drawal between 3 and 6 months despite absence of long-
term evidence from randomized trials [25].
In line with previous analyses, we found no significant
difference in mortality between steroid withdrawal and
maintenance at any time point after transplantation
despite availability of long-term follow-up data in our
Table 3 Frequency and percentage of biopsy-confirmed acute
rejection within the first 6 months, between 7 and 12 months,
between 13 and 24 months, and between 25 and 60 months
after kidney transplantation are shown and compared between
the two treatment groups, steroid withdrawal and steroid
maintenance using a χ2 test
Time after
transplantation
Steroid withdrawal,
n (%)
Steroid maintenance,
n (%)
P value
0–6 months 53 (17.6) 348 (7.2) <0.001
7–12 months 8 (1.6) 16 (0.4) <0.001
13–24 months 10 (1.0) 21 (0.5) 0.2
25–60 months 12 (0.7) 36 (1.3) 0.1
Fig. 3 Shows hazard ratios and 95% confidence intervals for all-cause mortality with functional graft estimated from the Cox supermodel. The rate
of death was not different between patients withdrawn from steroids compared to patients maintained on steroids at any landmark time
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registry. However, this does not only suggest that steroid
withdrawal is not associated with an increased mortality
but also that the desired survival benefit from discon-
tinuation of long-term steroid maintenance might be
absent. Although a statistically non-significant trend
towards reduced mortality in patients who were with-
drawn from steroids from 4 years after transplantation
onwards can be discussed considering our results. A
meta-analysis published in 2010 reported a reduction in
cardiovascular risk, but analyses were based on surrogate
outcomes rather than observed events of cardiovascular
endpoints [48]. In contradiction, a review of the litera-
ture assessing long-term adverse effects of steroid treat-
ment in rheumatic diseases reported no excess of
cardiovascular disease [49]. The authors discussed that
the overall fear of steroid-associated toxicity is probably
overestimated in low dose long-term steroid treatment,
but do acknowledge that additional risk factors, such as
obesity, hypertension and diabetes, merit more careful
observation of harmful side-effects associated with steroids.
Although these findings in patients with rheumatic diseases
might not be extrapolated to kidney transplant recipients,
the absence of evidence on harmful effects of steroid with-
drawal on mortality from controlled data combined with
our findings justifies steroid withdrawal beyond 18 months
after transplantation, as steroids beyond that time point are
no longer required to protect the renal transplant.
When interpreting our study, some important limita-
tions, in particular in relation to the retrospective nature
of the collected data, need to be taken into account.
Although we applied an advanced modelling approach
with dynamic propensity score matching to address con-
founding by indication, our results may still be affected
by unmeasured confounders which cannot be ruled out
in any observational study [50]. Further, the choice of
landmark time intervals potentially introduced survivor
bias, namely that a patient has to survive until the next
landmark time in order to be correctly classified and
counted in the analysis, but should be non-differential
between groups as this type of bias affects both steroid
groups equally. However, the alternative to use shorter
time intervals would have inflated the variance due to
smaller sample sizes within the landmark-specific
models. It has been recently discussed in the epidemio-
logic literature that a small non-differential bias should
be preferred over inflation of variances in such circum-
stances [51]. Our study population is representative for a
Central European, primarily Caucasian, population and
results might thus not be generalizable to populations in
other regions of the world or with different ethnic
backgrounds.
Our study has a number of strengths. First and fore-
most, the availability of long-term outcome data of high
quality in a well-maintained national registry with
negligible numbers of patients lost to follow-up. Addi-
tionally, we have a wide range of available information
that is periodically updated in the registry for multivari-
able adjustment. Furthermore, we have a large sample
size of several thousand transplant recipients with a suf-
ficiently large number of patients who were withdrawn
from steroids to conduct adequate regression analyses,
while the majority of existing trials included fewer than
300 participants [11]. Besides the available data itself, we
meticulously computed landmark time-specific hazard
ratios to determine the optimal time point for steroid
withdrawal using contemporary statistical methods.
Conclusions
In summary, randomized data do not provide conclusive
information to inform clinical practice on steroid with-
drawal in regard to long-term outcomes or optimal tim-
ing strategies for steroid withdrawal in kidney transplant
recipients. Our study is the first to analyze multiple time
points of steroid withdrawal with significant longer
follow-up and suggests that the optimal time point for
steroid withdrawal in kidney transplant recipients is be-
yond the first 18 months after transplantation.
Additional file
Additional file 1: Figure S1. Schematic representation of the landmark
Cox supermodel with dynamic propensity score-matched cohorts at each
landmark. Figure S2. Schematic representation of the model building
procedure. Figure S3. Patients represented in Fig. 1 are those withdrawn
from steroids throughout the study period (2142 patients). Each bar represents
1 year after transplantation, and the height of the bar corresponds to
the percentage of patients withdrawn from steroids within this
timeframe. Table S1. The estimated odds ratios with 95% confidence
intervals are given for the stratified propensity score model (averaged
over all 60 imputed datasets). Figure S4. Shows plots of the cause-specific
cumulative incidence function for functional graft loss (a) and all-cause
mortality with functional graft (b) at specific landmark times after
transplantation for the propensity score-matched study cohort (pooled
over all 60 imputed datasets). Figure S5. Shows the log minus log plots
for functional graft loss (a) and all-cause mortality with functional graft
(b) at specific landmark times after transplantation for the propensity
score-matched study cohort (pooled over all 60 imputed datasets).
Figure S6. Shows the concatenated Cox supermodel for functional
graft loss (a) and all-cause mortality with functional graft (b) with
administrative restriction of follow-up at 5 years. By limiting follow-up
duration in the presence of non-proportional hazards, it can be
assessed whether results are sensitive to the proportionality of hazards.
Figure S7. Shows results of the sensitivity analysis for functional graft loss
(a) and all-cause mortality with functional graft (b) comparing results from
our main analysis to those achieved by a complete case analysis and an
analysis based on a restricted propensity score only using variables with less
than 10% missing values. Figure S8. For each patient who was withdrawn
from steroids within the study period (n = 2142), the difference in
cardiovascular risk factors (the number of blood pressure medications,
body mass index (BMI), serum cholesterol, fasting glucose) before and
after steroid withdrawal were calculated. We first calculated the mean
of all measurements within two landmarks before and after the time
point of steroid withdrawal for each of the variables, and then calculated
the difference in means. There was no difference in any of these surrogate
cardiovascular outcomes, indicating that steroid withdrawal did not lead to
an improvement of cardiovascular risk factors. (DOCX 451 kb)
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